Peptide record

Retatrutide

Mechanism

Triple incretin agonist peptide derived from a GIP backbone and engineered to activate GLP-1, GIP, and glucagon receptors, with non-natural residues and fatty-acid conjugation that confer long half-life and balanced multi-receptor signaling.25 65 75

Function

Investigational agent that produces very large body-weight reductions in early trials by simultaneously engaging GLP-1R, GIPR, and GCGR to enhance satiety, energy expenditure, and glycemic control.25 75

Receptor

GLP-1 receptor (GLP1R), GIP receptor (GIPR), and glucagon receptor (GCGR). 25 65 75

Sequence

Approximately 39-amino-acid synthetic peptide derived from a GIP scaffold with Aib residues and C20 fatty-diacid conjugation; triple-agonist design.65 75

Length

39 amino acids

Organism or Origin

Synthetic multi-agonist peptide inspired by human incretins and glucagon.65 75 80

Gene

Not assigned in the current dataset.

Sources

25What is the mechanism of action of Retatrutide? - Patsnap Synapse, https://synapse.patsnap.com/article/what-is-the-mechanism-of-action-of-retatrutide
65Retatrutide Molecular Structure and Properties | Peptide Protocol Wiki, https://www.peptideprotocolwiki.com/peptides/retatrutide/molecule
75Retatrutide: The Triple Hormone Agonist (GLP-1/GIP/Gluc, https://formblends.com/research/glp-1/retatrutide-triple-agonist-guide
80GLP-1 Localisation and Proglucagon Gene Expression in ..., https://pmc.ncbi.nlm.nih.gov/articles/PMC6200298/

GLP-1 Receptor Agonists (Semaglutide Focus)